These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21515864)

  • 1. Adaptive trial design: its growing role in clinical research and implications for pharmacists.
    Cirulli J; McMillian WD; Saba M; Stenehjem D
    Am J Health Syst Pharm; 2011 May; 68(9):807-13. PubMed ID: 21515864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adaptive trial designs in drug development.
    Curtin F; Heritier S
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):727-736. PubMed ID: 28434375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacists and research: experts seek practitioner experience.
    Kaldy J
    Consult Pharm; 2009 Jul; 24(7):504-10. PubMed ID: 19689179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology.
    Elman SA; Ware JH; Gottlieb AB; Merola JF
    J Invest Dermatol; 2016 Jul; 136(7):1325-1329. PubMed ID: 27157773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
    Kirschenbaum BE
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
    Chuang-Stein C; Beltangady M
    J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive design of confirmatory trials: Advances and challenges.
    Lai TL; Lavori PW; Tsang KW
    Contemp Clin Trials; 2015 Nov; 45(Pt A):93-102. PubMed ID: 26079372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance.
    Bucci-Rechtweg C; Siapkara A; An Haack Bonnet K; Corriol Rohou S; Haf Davies E; Dehlinger Kremer M; Gamalo M; Moreno C; Nelson RM; Thomas Turner R
    Clin Trials; 2023 Feb; 20(1):13-21. PubMed ID: 36341541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
    Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
    J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development.
    Quinlan J; Gaydos B; Maca J; Krams M
    Clin Trials; 2010 Apr; 7(2):167-73. PubMed ID: 20338900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of adaptive design in r&d in Japan.
    Takeuchi M
    J Formos Med Assoc; 2008 Dec; 107(12 Suppl):9-13. PubMed ID: 19129040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shuffling Adaptive Clinical Trials.
    Gokhale SG; Gokhale S
    Am J Ther; 2016; 23(3):e663-9. PubMed ID: 23751329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration.
    Brannath W; Burger HU; Glimm E; Stallard N; Vandemeulebroecke M; Wassmer G
    J Biopharm Stat; 2010 Nov; 20(6):1125-31. PubMed ID: 21058108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.